Every quarter, each drugmaker rolls out its own list of hope-in-a-bottle drugs. You know the ones: The products that are growing much faster than anything else in a company's line-up. For some, it's a way to offer light at the end of a dark tunnel. For others, it's sort of an I.O.U. to the future. For a few lucky ones, it's a well-deserved fanfare.
Drugmakers raise U.S. prices to make more money. This isn't a surprise to anyone. It's a basic business strategy, and the U.S. market is among the few where pharma companies still have considerable pricing power. But thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage.
Prominent cancer doctors have balked at adopting a new Sanofi drug, Zaltrap, because they decided its benefits weren't worth the cost. Pharmacy benefits managers, notably Express Scripts, have nixed drugs from their formularies in favor of competing--and less expensive--options. And Gilead Sciences' pricing poster child Sovaldi has private payers and government programs so spooked, they're considering limiting its use to the sickest patients, at least until they can use soon-to-be-approved rivals to negotiate better pricing. Click here to read the full report on FiercePharmaMarketing >>
Drugmakers are adept at the one-way communication known as direct-to-consumer advertising, and some of them deal well with the media. Some even know how to work with patient groups. Back-and-forth with doctors? Pharma's daily bread.
But put your average, everyday drug company in the middle of a public conversation, and it freezes up. In fact, of the 50 largest drugmakers worldwide, only half even dabble in social media. Only 10 use all three of the oldest, biggest social sites--Facebook, Twitter and YouTube--according to a new study by the IMS Institute for Healthcare Informatics. And within that small group, few are actually interacting with patients and the public. Click here to read the full report on FiercePharmaMarketing >>
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
The launch of a generic of a key product in the U.S. always makes a sales organization uneasy because it inevitably means layoffs. But the last thing any sales team wants to hear is that its boss will have to lay off pretty much everyone if a generic comes to market. Yet that is what Hospira told a court is in store if it doesn't block copies of its sedative Precedex. Read more >>
AbbVie's waiting for FDA approval on a hepatitis C combo therapy. OraSure makes a rapid test to detect the virus. And professional truck drivers in the U.S. are more than 5 times as likely as other Americans to have it.
Back in April, Merck rolled out its America's Diabetes Challenge: Get to Your Goals campaign, aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck has a new-but-similar campaign launching, but with a tighter focus: the Hispanic community, which is disproportionately affected by the disease.
What makes a 5-year exclusivity period? Under U.S. law, it's the 5 years after FDA starts the clock ticking. Eisai has no qualms about that. But the Japanese drugmaker says the agency started that clock much too soon for two of its products--and it's suing the FDA to change that.
Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.
Almost half of doctors bar their doors to pharma sales reps some way, somehow. What with all the talk about rep access to physicians, that state of things may seem quote-unquote normal. But it's not. Just 6 years ago, the numbers were quite different.